CNBC

AstraZeneca targets $80 billion in total revenue by 2030 in 'post-Covid era'

Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023. AstraZeneca said it will focus on its oncology, ...
Reuters

New data finds AstraZeneca booster generates higher antibodies against Omicron

(Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant and ...

AstraZeneca sees higher 2022 sales even as COVID boost wanes

AstraZeneca raised its annual dividend for the first time in a decade on Thursday and forecast higher sales for 2022 as new ...
Time

COVID-19 Booster Shots Are Still Controversial—Even for the Immunocompromised People Who Likely Need Them the Most

Ducharme is a contributor to TIME. A health worker in Chile vaccinates someone with an AstraZeneca shot as a third booster dose against COVID-19 on Aug. 10, 2021. Ducharme is a contributor to TIME.
RAPS

Recon: Pfizer, BioNTech seek vaccine EUA for children under 5; EU authorizes AstraZeneca COVID booster

Regulatory Recon is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe. A story’s inclusion in ...